TABLE 1.
Antibiotic susceptibility patterns of 575 carbapenem-resistant K. pneumoniaea
| Antibiotic | % S | % I/SDD | % R | MIC data (mg/L) |
||
|---|---|---|---|---|---|---|
| MIC50 | MIC90 | Range | ||||
| Ertapenem | 0.0 | 1.6 | 98.4 | ≥32 | ≥32 | ≤1 to ≥32 |
| Doripenem | 7.0 | 5.9 | 87.1 | 16 | ≥32 | ≤0.5 to ≥32 |
| Imipenem | 5.6 | 4.0 | 90.4 | 16 | ≥32 | ≤0.5 to ≥32 |
| Meropenem | 6.6 | 5.6 | 87.8 | ≥32 | ≥32 | ≤0.5 to ≥32 |
| Aztreonam | 4.9 | 1.4 | 93.7 | ≥64 | ≥64 | ≤2 to ≥64 |
| Cefepime | 5.0 | 11.0 | 84.0 | ≥64 | ≥64 | ≤1 to ≥64 |
| Piperacillin-tazobactam | 0.4 | 3.1 | 96.5 | ≥128/4 | ≥128/4 | 8/4 to ≥128/4 |
| Levofloxacin | 21.1 | 12.5 | 66.4 | 16 | ≥64 | ≤0.25 to ≥64 |
| Amikacin | 72.7 | 2.1 | 25.2 | 8 | ≥128 | ≤4 to ≥128 |
| Polymyxin B | - | 88.9 | 11.1 | 0.5 | 4 | ≤0.25 to ≥16 |
| Tigecycline | 88.3 | 7.5 | 4.2 | 1 | 4 | ≤0.25 to ≥16 |
a
The categorical susceptibilities were determined using CLSI breakpoints, except for tigecycline (FDA). S, susceptible; I, intermediate; SDD, susceptible dose-dependent; R, resistant; MIC, minimum inhibitory concentration.